flow trial semaglutide kidney outcomes Long-term of in obesity and cardiovascular disease in the SELECT flow trial semaglutide kidney outcomes
Description
In subjects without type 1 diabetes, insulin is secreted from the pancreas into the portal vein, where 50-80% of insulin is metabolized in the first hepatic pass
The maintenance trial (NCT06859268) tests whether patients can reduce their retatrutide dose after achieving significant weight loss
Experts not involved with the study hailed the breakthrough, saying it could have a transformational impact on the lives of many patients
Corbin, K
[DOI] [PMC free article] [PubMed] [Google Scholar] 81.de Vrind VAJ, van t Sant LJ, Rozeboom A, Luijendijk-Berg MCM, Omrani A, Adan RAH
